Cellino Biotech, a pioneering biotechnology company based in Cambridge, Massachusetts, has made an exciting announcement with the appointment of Ed Tekeian as their Senior Vice President of Engineering. Tekeian, a seasoned engineering leader with a remarkable track record in developing innovative products, is set to oversee the advancement of Cellino’s scalable manufacturing platform for personalized regenerative medicines.

With over 30 years of experience in both the hardware and software industries, Tekeian’s expertise spans various domains, including spearheading the development of software applications for 3D printers and FDA-approved medical devices. His appointment signifies a strategic move for Cellino as they continue to push boundaries in the realm of regenerative therapies.

Matthias Wagner, Co-Founder & Chief Technology Officer of Cellino, expressed his enthusiasm for Tekeian joining the team, highlighting his multidisciplinary engineering leadership experience and proven success in delivering products that have positively impacted numerous patients. Tekeian, in turn, shared his excitement about the opportunity to contribute to technologies with significant patient impact and expressed his admiration for Cellino’s vision of making patient-specific cells accessible to all.

Tekeian’s impressive career includes leadership roles in notable companies such as Formlabs, Kuvée, Sample 6 Technologies, and 3M Health Care. His extensive background in leading mechanical, electrical engineering, software, customer, and manufacturing teams positions him well to drive Cellino’s mission of creating a robust platform for regenerative medicine.

Cellino Biotech is dedicated to developing an ultra-scalable, autonomous biomanufacturing platform aimed at providing personalized regenerative medicines. With Tekeian on board, the company is poised to accelerate its efforts towards making patient-specific cells more widely accessible, potentially revolutionizing the landscape of healthcare on a global scale.

As Cellino continues to innovate and expand its capabilities, the inclusion of Ed Tekeian in a leadership role signals a significant step forward in the company’s journey towards empowering individuals with personalized regenerative therapies. The appointment underscores Cellino’s commitment to leveraging cutting-edge technologies for the betterment of healthcare worldwide.